Materias dentro de su búsqueda.
Mostrando 1,801 - 1,820 Resultados de 2,901 Para Buscar 'Health', tiempo de consulta: 0.06s Limitar resultados
  1. 1801
    Clinical review report Levodopa/Carbidopa (Duodopa) (Abbvie Corporation)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  2. 1802
    Clinical review report Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  3. 1803
    Clinical review report Fluocinolone acetonide intravitreal implant (Iluvien) (Knight therapeutics inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  4. 1804
    Clinical review report Emtricitabine/tenofovir alafenamide fumarate (Descovy)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  5. 1805
    Clinical review report Edoxaban (Lixiana)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  6. 1806
    Clinical review report Dolutegravir (Tivicay)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  7. 1807
    Clinical review report Dapagliflozin (Forxiga)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  8. 1808
    Clinical review report Cysteamine delayed-release capsules (Procysbi) Horizon Pharma Ireland Ltd
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  9. 1809
    Clinical review report Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) (Recordati Rare Diseases Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  10. 1810
    Clinical review report Apomorphine (Movapo) (Paladin Labs, Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  11. 1811
    CADTH reimbursement recommendation : Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency). Emicizumab (Hemlibra)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  12. 1812
    CADTH Canadian drug expert committee recommendation (final) : indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia -- UCB Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  13. 1813
    CADTH Canadian Drug Expert Committee recommendation : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK-Nitisinone - )
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  14. 1814
    CADTH Canadian Drug Expert Committee final recommendation Tiotropium/Olodaterol (Inspiolto Respimat - Boehringer Ingelheim Canada Ltd.) indication : chronic obstructive pulmonary disease
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  15. 1815
    CADTH Canadian Drug Expert Committee final recommendation Tesamorelin (Egrifta -- Theratechnologies Inc.) indication : HIV-associated lipohypertherapy
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  16. 1816
    CADTH Canadian Drug Expert Committee final recommendation Propiverine hydrochloride (Mictoryl/Mictoryl Pediatric--Duchesnay Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  17. 1817
    CADTH Canadian Drug Expert Committee final recommendation Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  18. 1818
    CADTH Canadian Drug Expert Committee final recommendation Edoxaban : Lixiana-Servier Canada Inc. : indication : venous thromboembolic events
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  19. 1819
    CADTH Canadian Drug Expert Committee final recommendation Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  20. 1820
    CADTH Canadian Drug Expert Committee final recommendation Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico

Herramientas de búsqueda: